AMY-101 is under clinical development by Amyndas Pharmaceuticals and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect AMY-101’s likelihood of approval (LoA) and phase transition for Glomerulonephritis took place on 03 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their AMY-101 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
AMY-101 (Cp-40) is under development for the treatment of PNH (Paroxysmal Nocturnal Hemoglobinuria), kidney transplantation, C3 glomerulonephritis, periodontitis and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).The drug candidate acts by targeting complement C3. It is administered through subcutaneous or intravenous drip routes. The drug candidate is developed using technology for modulating the complement system.The drug candidate was also under development for the treatment of age related macular degeneration.
Quick View AMY-101 LOA Data
|Highest Development Stage|